Press Release · Press Releases
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase III HARMONi-GI1 trial (AK112-309). The study evaluated first-in-class ivonescimab plus...
This press release summary is reproduced from the issuer's public feed.
Read the full release at PR NewswireOriginal publisher: PR Newswire
Spotted an error? Request a correction · Corrections Policy
Related stories
In HelloNation, Insulation Expert Mike Mancuso Explains Why Air Sealing Should Come Before Adding Insulation
The article explains how sealing air leaks first helps insulation improve comfort, energy performance, and moisture control. CLARKS SUMMIT, Pa., Oct. 25, 2026 /PRNewswire/ -- Why should you air seal your home before adding insulation? A HelloNation article featuring insights from...
PR Newswire ·
INVESTOR DEADLINE: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline
SAN DIEGO, Oct. 25, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, all dates inclusive (the "Class Period"), have until Monday, November 2, 2026 to...
PR Newswire ·
INVESTOR DEADLINE: Gildan Activewear Inc. Investors with Substantial Losses May Seek to Lead the Gildan Activewear Class Action Lawsuit Before December 14, 2026 Deadline - GIL
SAN DIEGO, Oct. 25, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Gildan Activewear Inc. (NYSE: GIL) publicly traded securities between February 19, 2025 and June 15, 2026, both dates inclusive (the "Class Period"), have...
PR Newswire ·
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and...
PR Newswire ·
LexisNexis Coplogic Solutions Introduces Field Clarity for LexisNexis® Desk Officer Reporting System (DORS) at IACP 2026
A new, modern DORS and Field Clarity, the First AI-Guided Smartphone Video Assistant, Enhances Community Experience and Helps Improve Evidence, Case Building ORLANDO, Fla., Oct. 25, 2026 /PRNewswire/ -- LexisNexis® Coplogic™ Solutions today announced its modernized LexisNexis® Desk...
PR Newswire ·
Monster Energy and Call of Duty® Take Over Cosm Los Angeles for Immersive Modern Warfare® 4 Launch Celebration
Celebrities, athletes and creators came together for an action-packed night of gaming, immersive entertainment and exclusive experiences on Cosm's massive Shared Reality Display. INGLEWOOD, Calif., Oct. 25, 2026 /PRNewswire/ -- Monster Energy transformed Cosm Los Angeles into the ultimate...
PR Newswire ·